Nicholas Wald | Academic Influence

Nicholas Wald's AcademicInfluence.com Rankings

Nicholas Wald

Mathematics

#4146

World Rank

#5953

Historical Rank

Statistics

#201

World Rank

#254

Historical Rank

Measure Theory

#311

World Rank

#475

Historical Rank

mathematics Degrees

Download Badge

Mathematics

Nicholas Wald's Degrees

Bachelors Mathematics University of Oxford
PhD Statistics University of Oxford

Similar Degrees You Can Earn

Best Online Bachelor's in Math 2025

Why Is Nicholas Wald Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Sir Nicholas John Wald FRS, FRCP, FMedSci, qualified in medicine from University College London in 1967. He is currently honorary professor of preventive medicine, University College London, honorary professor, Population Health Research Institute, St George's, University of London, visiting professor, University of Oxford, and honorary consultant and adjunct professor, Brown University, Rhode Island. He was professor of environmental and preventive medicine from 1983 to 2019 at Barts and The London School of Medicine and Dentistry. He was co-founder and director of the Wolfson Institute of Preventive Medicine.

(See a Problem?)

Nicholas Wald's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies (2009) (2510)
Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. (2002) (1883)
Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis (2003) (1769)
A strategy to reduce cardiovascular disease by more than 80% (2003) (1583)
Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. (1991) (1416)
By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? (1994) (1297)
Interpretation of the evidence for the efficacy and safety of statin therapy (2016) (1290)
Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials (2003) (1093)
Maternal serum screening for Down's syndrome in early pregnancy. (1988) (952)
First-trimester or second-trimester screening, or both, for Down's syndrome. (2005) (908)
Randomized trial of preventive angioplasty in myocardial infarction. (2013) (877)
Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. (2009) (798)
The accumulated evidence on lung cancer and environmental tobacco smoke (1997) (742)
First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). (2003) (699)
Environmental tobacco smoke exposure and ischaemic heart disease: an evaluation of the evidence (1997) (629)
By how much does dietary salt reduction lower blood pressure? III--Analysis of data from trials of salt reduction. (1991) (536)
MATERNAL SERUM-ALPHA-FETOPROTEIN MEASUREMENT IN ANTENATAL SCREENING FOR ANENCEPHALY AND SPINA BIFIDA IN EARLY PREGNANCY Report of U.K. Collaborative Study on Alpha-fetoprotein in Relation to Neural-tube Defects (1977) (476)
Integrated screening for Down's syndrome based on tests performed during the first and second trimesters. (1999) (460)
Antenatal thyroid screening and childhood cognitive function. (2012) (430)
Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. (2005) (427)
MATERNAL SERUM ALPHA-FETOPROTEIN MEASUREMENT: A SCREENING TEST FOR DOWN SYNDROME (1984) (410)
Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. (1998) (385)
By how much does dietary salt reduction lower blood pressure? I--Analysis of observational data among populations. (1991) (383)
Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study (1994) (348)
When can a risk factor be used as a worthwhile screening test? (1999) (340)
European Code Against Cancer and scientific justification: third version (2003). (2003) (332)
Assessing possible hazards of reducing serum cholesterol (1994) (321)
Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. (2003) (319)
Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome (1988) (310)
LOW SERUM-VITAMIN-A AND SUBSEQUENT RISK OF CANCER Preliminary Results of a Prospective Study (1980) (278)
Antenatal maternal serum screening for Down's syndrome: results of a demonstration project. (1992) (277)
Does breathing other people's tobacco smoke cause lung cancer? (1986) (268)
Controlled trial of three different antismoking interventions in general practice. (1984) (267)
Risk factor thresholds: their existence under scrutiny (2002) (267)
Strategies for prevention of osteoporosis and hip fracture. (1991) (261)
Combining Ultrasound and Biochemistry in First‐Trimester Screening for Down's syndrome (1997) (260)
Antenatal screening for Down's syndrome. (1992) (255)
Apolipoproteins and ischaemic heart disease: implications for screening (1994) (254)
UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening (2015) (250)
By how much does dietary salt reduction lower blood pressure? I--Analysis of observational data among populations. (1991) (249)
Fetal loss in Down syndrome pregnancies (1999) (231)
PRENATAL SCREENING FOR DOWN'S SYNDROME USING INHIBIN‐A AS A SERUM MARKER (1996) (229)
How effective is nicotine replacement therapy in helping people to stop smoking? (1994) (228)
UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer (2011) (228)
Trends in individual consumption of dietary fat in the United States, 1920-1984. (1990) (228)
Antenatal Screening for Down's Syndrome (1997) (223)
Adult height and the risk of cause-specific death and vascular morbidity in 1 million people: individual participant meta-analysis. (2012) (220)
Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence (2006) (213)
Randomized trial of folic acid supplementation and serum homocysteine levels. (2001) (212)
Endometrial Thickness as a Test for Endometrial Cancer in Women With Postmenopausal Vaginal Bleeding (2002) (209)
Plasma retinol, beta-carotene and vitamin E levels in relation to the future risk of breast cancer. (1984) (205)
Glycated hemoglobin measurement and prediction of cardiovascular disease. (2014) (189)
The underlying risk of death after myocardial infarction in the absence of treatment. (2002) (187)
Why heart disease mortality is low in France: the time lag explanation. (1999) (185)
URINARY COTININE AS MARKER OF BREATHING OTHER PEOPLE'S TOBACCO SMOKE (1984) (182)
The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. (2016) (178)
AMNIOTIC-FLUID ACETYLCHOLINESTERASE AS A POSSIBLE DIAGNOSTIC TEST FOR NEURAL-TUBE DEFECTS IN EARLY PREGNANCY (1979) (175)
Association between Atherosclerotic Diseases and Carboxyhaemoglobin Levels in Tobacco Smokers (1973) (172)
Environmental tobacco smoke and ischemic heart disease. (2003) (169)
Helicobacter pylori infection and mortality from ischaemic heart disease: negative result from a large, prospective study (1997) (166)
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases (2007) (155)
Plasma retinol, beta-carotene and vitamin E levels in relation to the future risk of breast cancer. (1988) (152)
Prevention of blindness by screening for diabetic retinopathy: a quantitative assessment. (1989) (152)
International Smoking Statistics (2002) (151)
UKCCCR multicentre randomised controlled trial of one and two view mammography in breast cancer screening (1995) (151)
Antenatal screening for Down's syndrome with the quadruple test (2003) (139)
Randomized Polypill Crossover Trial in People Aged 50 and Over (2012) (138)
Cigarette consumption and serum cotinine in relation to birthweight (1987) (137)
Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy (1996) (137)
Current concepts in screening for noncommunicable disease: World Health Organization Consultation Group Report on methodology of noncommunicable disease screening (2005) (135)
Child-Parent Familial Hypercholesterolemia Screening in Primary Care. (2016) (134)
Screening for osteoporosis (1992) (134)
First and Second Trimester Antenatal Screening for Down's Syndrome: The Results of the Serum, Urine and Ultrasound Screening Study (SURUSS) (2003) (129)
First trimester concentrations of pregnancy associated plasma protein A and placental protein 14 in Down's syndrome. (1992) (128)
Risk‐based prenatal screening for trisomy 18 using alpha‐fetoprotein, unconjugated oestriol and human chorionic gonadotropin (1995) (128)
A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. (2016) (127)
The age and origin of the Pacific islands : a geological overview (2008) (125)
Folic acid and the prevention of neural-tube defects. (1997) (118)
Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alphafetoprotein level (1988) (117)
Screening for Future Cardiovascular Disease Using Age Alone Compared with Multiple Risk Factors and Age (2011) (116)
Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980 793 adults from 68 prospective studies (2018) (115)
Placebo controlled trial of nicotine chewing gum in general practice. (1984) (112)
The UK Lung Screen (UKLS): Demographic Profile of First 88,897 Approaches Provides Recommendations for Population Screening (2014) (111)
MATERNAL SERUM-ALPHA-FETOPROTEIN AND LOW BIRTH-WEIGHT (1977) (110)
The dose-response relationship between cigarette consumption, biochemical markers and risk of lung cancer. (1997) (109)
Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in twin pregnancies: implications for screening for Down's syndrome (1991) (109)
Serum alpha-tocopherol concentration in relation to subsequent colorectal cancer: pooled data from five cohorts. (1992) (108)
Changes in atopy over a quarter of a century, based on cross sectional data at three time periods (2005) (103)
Serum cholesterol and ischaemic heart disease. (1995) (103)
Prevention of Neural Tube Defects: A Cross-Sectional Study of the Uptake of Folic Acid Supplementation in Nearly Half a Million Women (2014) (100)
Prenatal diagnosis of spina bifida and anencephaly by maternal serum-alpha-fetoprotein measurement. A controlled study. (1974) (99)
Serum markers for Down's syndrome in women who have had in vitro fertilisation: implications for antenatal screening (1999) (99)
UK Smoking Statistics (1988) (94)
Antenatal and neonatal screening (2000) (93)
Relation of urinary cotinine concentrations to cigarette smoking and to exposure to other people's smoke. (1990) (91)
Blood folic acid and vitamin B12 in relation to neural tube defects (1996) (91)
The illusion of polygenic disease risk prediction (2019) (91)
Randomised Trial of Text Messaging on Adherence to Cardiovascular Preventive Treatment (INTERACT Trial) (2014) (88)
Chlamydia pneumoniae infection and mortality from ischaemic heart disease: large prospective study (2000) (88)
Combining nuchal translucency and serum markers in prenatal screening for Down syndrome in twin pregnancies (2003) (86)
Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis (2007) (85)
Prospective study of effect of switching from cigarettes to pipes or cigars on mortality from three smoking related diseases (1997) (85)
An ecological study of serum cholesterol and ischaemic heart disease between 1950 and 1990. (1994) (83)
THE EFFECT OF MATERNAL WEIGHT ON MATERNAL SERUM ALPHA‐FETOPROTEIN LEVELS (1981) (83)
Reporting the assessment of screening and diagnostic tests (1989) (81)
Report of the European Society for Mastology Breast Cancer Screening Evaluation Committee (1993) (1993) (79)
FIRST-TRIMESTER BIOCHEMICAL SCREENING FOR DOWN SYNDROME (1988) (79)
By how much does dietary salt reduction lower blood pressure? II--Analysis of observational data within populations. (1991) (78)
Reconciling the Evidence on Serum Homocysteine and Ischaemic Heart Disease: A Meta-Analysis (2011) (76)
Couple screening for cystic fibrosis (1993) (76)
Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer (1995) (75)
Mortality in relation to tar yield of cigarettes: a prospective study of four cohorts (1995) (73)
Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies (2006) (72)
A case-control study of dietary carotene in men with lung cancer and in men with other epithelial cancers. (1991) (70)
Public health failure in the prevention of neural tube defects: time to abandon the tolerable upper intake level of folate (2018) (69)
Birth prevalence of down's syndrome in England and Wales (1991) (68)
The evaluation of cascade testing for familial hypercholesterolemia (2012) (68)
Sequential and contingent prenatal screening for Down syndrome (2006) (67)
Headaches and the Treatment of Blood Pressure: Results From a Meta-Analysis of 94 Randomized Placebo-Controlled Trials With 24 000 Participants (2005) (67)
SERUM COTININE LEVELS IN PIPE SMOKERS: EVIDENCE AGAINST NICOTINE AS CAUSE OF CORONARY HEART DISEASE (1981) (66)
Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme (2003) (65)
The effect of smoking in pregnancy on maternal serum alpha‐fetoprotein, unconjugated oestriol, human chorionic gonadotrophin, progesterone and dehydroepiandrosterone sulphate levels (1990) (64)
Neonatal screening for cystic fibrosis (1998) (62)
VALIDATION OF STUDIES ON LUNG CANCER IN NON-SMOKERS MARRIED TO SMOKERS (1984) (62)
The use of free β‐hCG in antenatal screening for Down's syndrome (1993) (61)
Breast cancer screening: the current position. (1991) (61)
Selective miscarriage of Down's syndrome fetuses in women aged 35 years and older (1995) (60)
Cigarette smoking and levels of maternal serum alpha-fetoprotein, unconjugated estriol, and hCG: impact on Down syndrome screening. (1993) (60)
Couple screening for cystic fibrosis (1991) (60)
SMALL BIPARIETAL DIAMETER OF FETUSES WITH SPINA BIFIDA: IMPLICATIONS FOR ANTENATAL SCREENING (1980) (59)
The efficacy of combining several risk factors as a screening test (2005) (58)
Amniotic fluid acetylcholinesterase measurement in the prenatal diagnosis of open neural tube defects. Second report of the collaborative acetylcholinesterase study (1989) (55)
The definition of screening (2001) (55)
Thyroid stimulating hormone and free thyroxine in pregnancy: expressing concentrations as multiples of the median (MoMs). (2014) (55)
The Performance of Blood Pressure and other Cardiovascular Risk Factors as Screening Tests for Ischaemic Heart Disease and Stroke (2004) (54)
Report of the European Society of Mastology Breast Cancer Screening Evaluation Committee * (1993) (54)
The distribution of nuchal translucency at 10–13 weeks of pregnancy (1998) (54)
Neural‐tube defects and vitamins: the need for a randomized clinical trial (1984) (53)
Use of carboxyhaemoglobin levels to predict the development of diseases associated with cigarette smoking. (1975) (51)
First- and second-trimester evaluation of risk (faster) trial: principal results of the NICHD multicenter down syndrome screening study (2003) (51)
Screening in early pregnancy for pre‐eclampsia using down syndrome quadruple test markers (2006) (51)
Serum albumin and mortality in the BUPA study. British United Provident Association. (1994) (51)
Occupational exposure to hydrazine and subsequent risk of cancer. (1984) (50)
Assessing risk factors as potential screening tests: a simple assessment tool. (2011) (49)
Teleoanalysis: combining data from different types of study (2003) (49)
Maternal serum alpha-fetoprotein levels in multiple pregnancy. (1975) (49)
Guidance on terminology (2006) (48)
The impact of screening for open neural tube defects in England and Wales (1987) (48)
Nicotine, smoking, and the low tar programme (1989) (48)
Grapefruit Juice and Statins. (2016) (48)
CARBOXYHÆMOGLOBIN LEVELS IN SMOKERS OF FILTER AND PLAIN CIGARETTES (1977) (47)
Cigarette smoking patterns during the working day. (1977) (46)
Influence of maternal smoking on the birth prevalence of Down syndrome and on second trimester screening performance (2002) (46)
Integrated Screening for Down’s Syndrome Based on Tests Performed During the First and Second Trimesters (2000) (46)
Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis (2021) (45)
Child-parent screening for familial hypercholesterolemia. (2011) (45)
Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in pregnancies with insulin‐dependent diabetes: implications for screening for Down's syndrome (1992) (45)
OVULATION INDUCTION AND NEURAL TUBE DEFECTS (1989) (45)
Second‐trimester prenatal screening markers for Down syndrome in women with insulin‐dependent diabetes mellitus (2004) (44)
Trends in tar, nicotine, and carbon monoxide yields of UK cigarettes manufactured since 1934. (1981) (44)
AMNIOTIC FLUID AFP LEVELS AND DOWN SYNDROME (1985) (44)
Measurement of activity of urea resistant neutrophil alkaline phosphatase as an antenatal screening test for Down's syndrome. (1990) (44)
Assay precision of serum α fetoprotein in antenatal screening for neural tube defects and Down's syndrome (2000) (43)
Cancer of the cervix uteri and vitamin A. (1986) (43)
Amniotic Fluid Acetylcholinesterase Electrophoresis as a Secondary Test in the Diagnosis of Anencephaly and Open Spina Bifida in Early Pregnancy: Report of the Collaborative Acetylcholinesterase Study (1982) (43)
Folic Acid and the Prevention of Neural Tube Defects (1993) (42)
Feasibility Study of a Randomised Trial of Ovarian Cancer Screening among the General Population (1994) (41)
Should folic acid fortification be mandatory? Yes (2007) (41)
Prevalence of neural tube defect pregnancies in England and Wales from 1964 to 2004 (2007) (40)
Neural tube defects and serum zinc (1993) (40)
MATERNAL SERUM ALPHA‐FETOPROTEIN AND BIRTH WEIGHT (1980) (40)
MATERNAL SERUM ALPHA‐FETOPROTEIN AND SPONTANEOUS ABORTION (1977) (40)
The extent of Down's syndrome screening in Britain in 1991 (1992) (39)
Ultrasound fetal femur length measurement in the screening for Down's syndrome (1989) (39)
Folic acid food fortification to prevent neural tube defects (1998) (39)
The tar reduction study: randomised trial of the effect of cigarette tar yield reduction on compensatory smoking. (1995) (38)
Quantifying the decline in the birth prevalence of neural tube defects in England and Wales (1999) (37)
8 Recent advances in screening for neural tube defects and Down's syndrome (1987) (36)
Retinol, beta-carotene and cancer. (1987) (36)
Folic acid and neural tube defects: the current evidence and implications for prevention. (2007) (35)
Folic acid and the prevention of neural tube defects (1995) (35)
MORTALITY FROM LUNG CANCER AND CORONARY HEART-DISEASE IN RELATION TO CHANGES IN SMOKING HABITS (1976) (35)
Empirical Validation of Risk Screening for Down's Syndrome (1996) (34)
International Commission for Protection against Environmental Mutagens and Carcinogens. ICPEMC publication no. 6: do treatments available for psoriasis patients carry a genetic or carcinogenic risk? (1981) (34)
Sharing Clinical Trial Data (2017) (34)
Screening for Abdominal Aortic Aneurysms (1994) (34)
Folic acid, pernicious anaemia, and prevention of neural tube defects (1994) (34)
EARLY ANTENATAL DIAGNOSIS OF EXOMPHALOS (1980) (33)
Multiple marker second trimester serum screening for pre-eclampsia (2001) (33)
Prenatal screening for serious congenital heart defects using nuchal translucency: a meta‐analysis (2008) (33)
Smoking, carbon monoxide and arterial disease. (1975) (33)
The importance of age in screening for cancer (1999) (32)
The polypill concept (2010) (32)
Prenatal biochemical screening for Down's syndrome and neural tube defects (1992) (30)
EFFECT OF GESTATIONAL AGE ON SCREENING FOR NEURAL-TUBE DEFECTS BY MATERNAL PLASMA-A.F.P. MEASUREMENT (1975) (30)
Biparietal diameter and crown‐rump length in fetuses with Down's syndrome: implications for antenatal serum screening for Down's syndrome (1993) (29)
On the estimation of the incubation period in malignant disease; the brief exposure case, leukemia. (1959) (29)
Is cascade testing a sensible method of screening a population for autosomal recessive disorders? (2004) (29)
CONGENITAL TALIPES AND HIP MALFORMATION IN RELATION TO AMNIOCENTESIS: A CASE-CONTROL STUDY (1983) (29)
Triploidy identified through second‐trimester serum screening (2005) (28)
Tests using single markers (2000) (27)
Preventive angioplasty in myocardial infarction. (2014) (27)
Incorporating DNA Sequencing into Current Prenatal Screening Practice for Down's Syndrome (2013) (27)
Sex differences in fetal size early in pregnancy. (1986) (27)
AFP and age screening for Down syndrome. (1988) (27)
Guidance on terminology. (1994) (26)
Screening for Down syndrome. (1989) (26)
Estimation of risk in second trimester serum screening for Down syndrome among women who have already had first trimester screening (2001) (26)
First trimester biochemical screening for Down's syndrome. (1994) (26)
Serum triglyceride: a possible risk factor for ruptured abdominal aortic aneurysm. (1998) (26)
Cystic fibrosis: selecting the prenatal screening strategy of choice (2003) (26)
Prenatal screening for open neural tube defects and Down syndrome: three decades of progress (2010) (25)
Prenatal reflex DNA screening for trisomies 21, 18, and 13 (2018) (25)
MATERNAL SERUM SPECIFIC BETA1-GLYCOPROTEIN IN PREGNANCIES ASSOCIATED WITH DOWN'S SYNDROME (1989) (25)
Vitamin B12 deficiency and the fortification of food with folic acid. (1995) (25)
MATERNAL SERUM ALPHA‐FETOPROTEIN SCREENING FOR OPEN NEURAL TUBE DEFECTS IN TWIN PREGNANCIES (1990) (25)
The Indian Polycap Study (TIPS) (2009) (25)
Tests using multiple markers (2000) (25)
Twinning and folic acid use (1999) (24)
SURUSS in perspective. (2005) (24)
False positive gel‐acetylcholinesterase results in blood‐stained amniotic fluids (1982) (24)
MATERNAL SERUM ALPHA‐FETOPROTEIN AND BIRTH WEIGHT IN TWIN PREGNANCIES (1978) (24)
Recent advances in screening for neural tube defects and Down's syndrome. (1987) (24)
Graphical presentation of distributions of risk in screening (2005) (23)
Lowering blood pressure to prevent myocardial infarction and stroke: A new preventive strategy (2005) (23)
Distribution of nuchal translucency in antenatal screening for Down's syndrome (2010) (23)
Prenatal screening for Down syndrome and neural tube defects in twin pregnancies (2005) (23)
Down's syndrome screening with nuchal translucency (1996) (22)
The effect of vitamin A supplementation on serum retinol and retinol binding protein levels. (1985) (22)
The selective miscarriage of Down's syndrome from 10 weeks of pregnancy (1996) (22)
ANTENATAL SCREENING FOR DOWN SYNDROME (1988) (22)
Improvements in antenatal screening for Down's syndrome (2013) (22)
Should a Reduction in All-Cause Mortality Be the Goal When Assessing Preventive Medical Therapies? (2017) (22)
Smoking tables for carbon monoxide? (1973) (22)
Effect of estimating gestational age by ultrasound cephalometry on the specificity of α‐fetoprotein screening for open neural‐tube defects (1982) (22)
Prenatal screening for Down syndrome: the problem of recurrent false‐positives (2004) (21)
Homocysteine and ischaemic heart disease. (1999) (21)
Quantifying the decline in the birth prevalence of neural tube defects in England and Wales. (2000) (21)
Detection of trisomy 18 and trisomy 13 using first and second trimester Down's syndrome screening markers (2013) (21)
Risk Estimation Versus Screening Performance: A Comparison of Six Risk Algorithms for Cardiovascular Disease (2012) (21)
European Society of Mastology Consensus Conference on breast cancer screening: report of the evaluation committee. (1994) (20)
Dietary salt and blood pressure. (1991) (20)
The polypill in the primary prevention of cardiovascular disease (2010) (20)
Cross‐trimester marker ratios in prenatal screening for Down syndrome (2006) (19)
Ductus Venosus Pulsatility Index as an Antenatal Screening Marker for Down'S Syndrome: Use with the Combined and Integrated Tests (2009) (19)
Guidance on terminology (2008) (19)
Repeat maternal serum alpha‐fetoprotein testing in antenatal screening programmes for Down's syndrome (1989) (19)
Serum alpha‐fetoprotein and neural tube defects in the first trimester of pregnancy (1993) (19)
A randomized double-blind crossover trial to investigate the efficacy of screening for adult hypothyroidism (2010) (18)
Populist instead of professional (2000) (18)
Birth prevalence of Down's syndrome in England and Wales 1990 to 1997 (1998) (18)
Antenatal screening for cystic fibrosis (1995) (18)
Ratio of amniotic fluid acetylcholinesterase to pseudocholinesterase as an antenatal diagnostic test for exomphalos and gastroschisis (1984) (18)
First trimester Down's syndrome screening marker values and cigarette smoking: new data and a meta-analysis on free β human chorionic gonadotophin, pregnancy-associated plasma protein-A and nuchal translucency (2008) (18)
Cost–benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke (2016) (18)
A survey of diagnostic amniocenteses in Oxford from 1974–1981 (1985) (18)
Routine Ultrasound Scanning for Congenital Abnormalities (1998) (16)
Performance of antenatal reflex DNA screening for Down’s syndrome (2015) (16)
First‐Trimester Nuchal Translucency Screening (2002) (16)
Multiple marker second trimester serum screening for pre-eclampsia. (2001) (16)
Information leaflets in medical screening (2006) (16)
Antenatal Screening for Down Syndrome Using Serum Placental Growth Factor with the Combined, Quadruple, Serum Integrated and Integrated Tests (2012) (15)
Further observations in connection with couple screening for cystic fibrosis (1995) (15)
Child-Parent Familial Hypercholesterolemia Screening in Primary Care. (2017) (15)
What is Case—Finding? (1996) (15)
Neural tube defects and serum zinc (1994) (15)
Pregnancies associated with low maternal serum alpha-fetoprotein concentrations. (1979) (15)
Implementation of a simple age-based strategy in the prevention of cardiovascular disease: the Polypill approach. (2012) (14)
European Society of Mastology Consensus Conference on Breast Cancer screening, Paris, 4-5 February 1993: report of the Evaluation Committee. (1994) (14)
Down's syndrome screening in UK (1996) (14)
Integration of child–parent screening and cascade testing for familial hypercholesterolaemia (2018) (14)
Ethical issues in randomised prevention trials. (1993) (14)
RAISED MATERNAL SERUM ALPHA-FETOPROTEIN LEVELS IN SUBSEQUENT PREGNANCIES (1981) (14)
Effect on down syndrome screening performance of adjusting for marker levels in a previous pregnancy (2006) (13)
Evidence against oral contraceptives as a cause of neuraltube defects (1982) (13)
Reliability of Statistics on Down's Syndrome Notifications (1997) (13)
Estimating risk of Down's syndrome. (1991) (13)
The value of early second trimester PAPP-A and ADAM12 in screening for pre-eclampsia (2012) (13)
Maternal serum thyroid antibodies in early pregnancy and fetal Down's syndrome (1988) (13)
Occupational Exposure to Hydrazine and Subsequent Risk of Lung Cancer: 50-Year Follow-Up (2015) (13)
Commentary: a brief history of folic acid in the prevention of neural tube defects. (2011) (13)
Refining the American guidelines for prevention of cardiovascular disease (2014) (13)
The quality control of alpha-fetoprotein reagents and assay for the antenatal screening and diagnosis of open neural-tube defects. (1980) (13)
Community Corner: Opening the Pandora's box of prenatal genetic testing (2011) (13)
Consequences for research if use of anonymised patient data breaches confidentiality (1999) (13)
Consensus Conference on Breast Cancer Screening (1994) (12)
Efficacy and safety of cholesterol-lowering treatment (2006) (12)
Use of unconjugated oestriol in screening for Down's syndrome (1993) (12)
Erratum to: Quantifying the health benefits of chronic disease prevention: a fresh approach using cardiovascular disease as an example (2014) (12)
Dietary salt and blood pressure (1994) (12)
Sensitivity of ultrasound in detecting spina bifida. (1991) (12)
Nuchal translucency and gestational age (2004) (12)
CONSORT statement on the reporting standards in clinical trials. Recommendations are inappropriate for trial reports. (1997) (12)
Reflex antenatal DNA screening for Down syndrome (2015) (11)
Folic acid in prevention of neural tube defects (1995) (11)
AMNIOTIC FLUID ACETYLCHOLINESTERASE (1981) (11)
Value of maternal serum unconjugated oestriol measurement in prenatal screening for Down's syndrome (1994) (11)
Down’s syndrome (2000) (11)
Repeat maternal serum testing in multiple marker down's syndrome screening programmes (1994) (11)
Quantifying the health benefits of chronic disease prevention: a fresh approach using cardiovascular disease as an example (2014) (11)
HOW MUCH CAN THE NHS AFFORD TO SPEND TO SAVE A LIFE OR AVOID A SEVERE DISABILITY? (1985) (10)
Diagnosis of Alzheimer's disease. (1991) (10)
Adding free to total prostate-specific antigen levels in trials of prostate cancer screening (2000) (10)
Systematic review of isolation policies in the hospital management of methicillin-resistant Staphylococcus aureus : A review of the literature with epidemiological and economic modeling (10)
Urgent need for folic acid fortification of flour and grains: response to the 2019 UK Government’s public consultation (2019) (10)
Homocysteine as a cause of ischemic heart disease: the door remains open. (2012) (10)
The Polypill in the prevention of cardiovascular disease. (2011) (10)
Folic acid fortification in the prevention of neural tube defects. (2004) (10)
Validation plots in antenatal screening for Down's syndrome (2006) (10)
Smoking and hormone-related disorders (1990) (10)
SCREENING FOR NEURAL-TUBE DEFECTS (1978) (10)
AMNIOCENTESES AND THE ALPHA-FETOPROTEIN SCREENING PROGRAMME (1979) (10)
Specifying a Gold Standard for the Validation of Fetal Fraction Estimation in Prenatal Screening. (2018) (10)
APOLIPOPROTEINS AND ISCHAEMIC HEART DISEASE (1995) (10)
Breast screening saves lives (2009) (9)
Maternal serum alpha-fetoprotein in relation to zygosity. (1979) (9)
Maternal serum α‐fetoprotein and low birth weight in relation to gestational age (1982) (9)
Reversing the obesity epidemic (2004) (9)
EFFECT OF GESTATIONAL AGE ON SCREENING FOR NEURAL-TUBE DEFECTS BY MATERNAL PLASMA-A. F. P. MEASUREMENT (1976) (9)
Discounting the Value of Life (2011) (9)
Use of overall population, center-specific, and sonographer-specific nuchal translucency medians in down syndrome screening: which is best? (Results from the faster trial) (2003) (9)
Estimating the risk of Down's syndrome in antenatal screening and the gestation at which this risk applies (2007) (9)
Choice of Serum Markers in Antenatal Screening for Down's Syndrome (1994) (9)
Calcium channel blockers and headache. (2007) (9)
Screening: a step too far. A matter of concern (2007) (9)
A 16-week, randomized, double-blind, placebo-controlled, crossover trial to quantify the combined effect of an angiotensin-converting enzyme inhibitor and a beta-blocker on blood pressure reduction. (2008) (9)
Alpha fetoprotein in the antenatal diagnosis of open neural tube defects. (1980) (9)
Body weight reduction to avoid the excess risk of type 2 diabetes. (2012) (8)
Repeat testing in antenatal screening for Down syndrome using dimeric inhibin‐A in combination with other maternal serum markers (2001) (8)
Nuchal translucency and trisomy 18 (1999) (8)
The use of free β‐hCG in antenatal screening for Down's syndrome (1994) (8)
Neural tube defects (2000) (8)
Simplification of biochemical screening for Down syndrome. (1989) (8)
First‐trimester amniotic fluid and extraembryonic coelomic fluid acetylcholinesterase electrophoresis (1992) (8)
Screening for abdominal aortic aneurysms. (1994) (8)
FETAL CALF SERUM AS CAUSE OF FALSE POSITIVE AMNIOTIC FLUID ACETYLCHOLINESTERASE GEL TESTS (1982) (8)
Down's syndrome screening in twin pregnancies (1995) (8)
Vitamin B-12 and folate deficiency in elderly persons. (2004) (8)
Adding ductus venosus blood flow as a categorical variable to the Combined and Integrated tests in Down's syndrome screening (2012) (7)
Maternal serum unconjugated estriol levels are lower in the presence of fetal Down syndrome. (1990) (7)
Prenatal screening for Down syndrome in twin pregnancies: Estimates of screening performance based on 61 affected and 7302 unaffected twin pregnancies (2018) (7)
First-trimester screening for Down's syndrome. (2004) (7)
Amniotic fluid acetylcholinesterase in the prenatal diagnosis of open neural tube defects and abdominal wall defects: A comparison of gel electrophoresis and a monoclonal antibody immunoassay (1990) (7)
The Journal of Medical Screening (1993) (7)
MATERNAL SERUM-COPPER CONCENTRATION AND NEURAL-TUBE DEFECTS (1977) (7)
Unconjugated estriol values between 14 and 22 weeks of gestation in relation to prenatal screening for Down syndrome (2012) (7)
MATERNAL SERUM ALPHA-FETOPROTEIN SCREENING FOR DOWN SYNDROME AND REPEAT TESTING (1986) (7)
Screening for pre-eclampsia using serum placental growth factor and endoglin with Down's syndrome Quadruple test markers (2012) (7)
Use of Free β-hCG in down's Syndrome Screening (1993) (7)
Cord serum alpha-fetoprotein and Down's syndrome. (1986) (7)
Mortality from aortic stenosis: prospective study of serum calcium and phosphate (2017) (7)
Alpha-fetoprotein screening for open spina bifida: effect of routine biparietal diameter measurement to estimate gestational age. (1984) (7)
Smoking and leukaemia. (1988) (7)
Nomogram for estimating an individual's risk of having a fetus with open spina bifida (1982) (6)
Small fetal transverse cerebellar diameter: a screening test for spina bifida (1994) (6)
Apolipoproteins and prediction of fatal myocardial infarction (2002) (6)
MATERNAL SERUM ALPHA‐FETOPROTEIN LEVELS IN TRIPLET AND QUADRUPLET PREGNANCY (1978) (6)
UK Lung Cancer RCT Pilot Screening Trial (2016) (6)
MATERNAL SERUM ALPHA‐FETOPROTEIN AND PREVIOUS NEURAL TUBE DEFECTS (1976) (6)
Lung Cancer and passive smoking. Increased risk is not disputed. (2000) (6)
Adipose tissue trans fatty acids and coronary heart disease (1995) (6)
Alpha fetoprotein screening and diagnosis of fetal open neural tube defects: the need for quality control. (1981) (6)
Folic acid and the prevention of neural tube defects: the need for public health action. (1995) (6)
ORGANISATION OF MATERNAL SERUM-α-FETOPROTEIN SCREENING FOR FETAL NEURAL-TUBE DEFECTS (1977) (6)
“Polypill” to fight cardiovascular disease: Authors' reply (2003) (6)
BREAST CANCER SCREENING (1987) (6)
Nuchal translucency and trisomy 18 (1999) (6)
The efficacy and safety of periodic mammographic breast cancer screening: summary of report of the European Society of Mastology. (1994) (6)
Ultrasound scanning for congenital abnormalities (2000) (6)
What is Genetic Screening Anyway? (1996) (6)
Attribution of time lag theory to explain French paradox (1999) (6)
Folic acid and neural tube defects. (2001) (6)
What are We Screening For? (1994) (6)
Correlations between nuchal translucency and serum markers in SURUSS (2004) (6)
UNITED KINGDOM LUNG CANCER SCREENING (UKLS) TRIAL (2011) (5)
Statins for people at low risk of cardiovascular disease (2012) (5)
RELATION BETWEEN MATERNAL SERUM AND AMNIOTIC FLUID AFP (1980) (5)
Issues in implementing prenatal screening for cystic fibrosis: Results of a working conference (1999) (5)
Repeat maternal serum testing for Down's syndrome screening using multiple markers with special reference to free alpha and free beta-hCG. (1998) (5)
The value of performing a dating scan on all women in antenatal screening for Down's syndrome and neural tube defects (1993) (5)
The use of free beta-hCG in antenatal screening for Down's syndrome. (1993) (5)
Screening for Down's syndrome using serum alpha fetoprotein. (1985) (5)
Inhibin‐A concentrations between 14 and 22 weeks of gestation (2008) (5)
Randomised trial of two-drug and four-drug maintenance chemotherapy in advanced or recurrent Hodgkin's disease. Medical Research Council's working party on lymphomas. (1979) (5)
MORTALITY FROM LUNG CANCER (1976) (5)
Multiple-marker screening for Down's syndrome: a method of assessing the statistical robustness of proposed tests (2008) (5)
Maternal alpha fetoprotein screening (1981) (5)
Cost-effectiveness of diagnosis of high blood pressure in primary care (2012) (5)
MATERNAL SERUM a-FETOPROTEIN LEVELS IN MULTIPLE PREGNANCY (1975) (5)
Death from ischaemic heart disease. (1977) (5)
Commentary: Disagreements are not substantial (1994) (5)
NICOTINE, CARBON MONOXIDE AND HEART DISEASE (1982) (5)
The effect of correlations between screening markers on screening performance (2007) (5)
Response to letter from Dr Lee (1991) (5)
First- and second-trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS) (vol 10, pg 56, 2003) (2006) (5)
Suspended judgment. Does taking extra vitamins prevent spina bifida? (1991) (5)
Folic acid and neural tube defects: Discovery, debate and the need for policy change (2022) (5)
The threat to the use of records and stored blood samples in medical screening research (2001) (5)
Lung cancer and passive smoking. (1990) (5)
Three stage contingent screening for Down syndrome (2006) (5)
Some Practical Issues in the Antenatal Detection of Neural Tube Defects and Down’s Syndrome (1991) (5)
The epidemiological approach: an introduction to epidemiology in medicine. (2004) (5)
Prenatal reflex DNA screening for trisomies 21, 18, and 13 (2017) (4)
Passive smoking and lung cancer - reply (1998) (4)
Screening for open neural-tube defects in England and Wales. (1979) (4)
Provide the citizens of New Zealand the miracle of folic acid fortification. (2003) (4)
Prenatal reflex DNA screening for Down syndrome: enhancing the screening performance of the initial first trimester test (2016) (4)
VITAMIN SUPPLEMENTATION FOR PREVENTION OF NEURAL TUBE DEFECT RECURRENCES (1983) (4)
Screening for future coronary heart disease (2005) (4)
Use of biological sample banks in epidemiological studies. (1985) (4)
The estimation of median nuchal translucency values between 10 and 14 weeks of pregnancy (2014) (4)
International smoking statistics (2nd edition). A collection of historical data from 30 economically developed countries (2004) (4)
AMNIOTIC FLUID ALPHA-FETOPROTEIN LEVELS IN DOWN SYNDROME (1986) (4)
MRC/BHF Heart Protection Study (2002) (4)
Screening, ethics, and the law. (1992) (4)
(2016). A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate risk. (2016) (4)
SCREENING FOR NEURAL-TUBE DEFECTS (1978) (4)
The controlled antenatal thyroid screening study (CATS) - first observations (2003) (4)
Folic acid in prevention of neural tube defects. (2016) (4)
Occupational exposure to hydrazine and subsequent risk of cancer. (1984) (4)
An audit of the detection of trisomy 18 in prenatal screening for Down syndrome using the Combined test (2011) (4)
Low maternal serum alpha‐fetoprotein and Down syndrome (1987) (4)
CUT-OFF LEVELS IN AFP SCREENING (1980) (4)
Examination for influenza IgA and IgM antibodies in pregnancies associated with fetal neural-tube defects. (1981) (4)
Compliance with screening for colorectal cancer. (1986) (4)
Letter: Variations in carboxyhaemoglobin levels in smokers. (1975) (4)
Cord serum alpha‐fetoprotein and maternal insulin‐dependent diabetes mellitus (1989) (4)
Assay precision of serum alphafetoprotein in antenatal screening for neural tube defects and Down's syndrome (vol 7, pg 74, 2000) (2000) (3)
Insulin dependent diabetes mellitus (IDDM) and first trimester markers in prenatal screening for Down syndrome (2016) (3)
Serum alpha-fetoprotein and neural tube defects in the first trimester of pregnancy. MRC Vitamin Study Research Group. (1993) (3)
Formulation for Cardiovascular Disease Prevention (2001) (3)
Folate and risk of cardiovascular disease (2003) (3)
When marginal costs and benefits should be used in screening (1996) (3)
Screening and preventive medication (2017) (3)
Neonatal Screening: Old Dogma or Sound Principle? (2007) (3)
Response to Walker (2018) (3)
Gestational age–based performance of down syndrome screening markers: results from the faster trial (2003) (3)
Guidance on Terminology (1994) (3)
Can the coverage of screening for cancer of the cervix be improved using the Electoral Register? A pilot study. (1985) (3)
Morbidity and mortality in relation to social class. (1972) (3)
Randomized Crossover Trial of Phosphate-binding Medication on Serum Phosphate Levels in Patients With Aortic Stenosis (2019) (3)
ROUTINE TESTING FOR ALPHA-FETOPROTEIN IN AMNIOTIC FLUID (1976) (3)
The Medical Screening Society (2002) (3)
Screening needs a fresh approach (2007) (3)
Organisation of maternal serum alpha fetoprotein screening for fetal neural-tube defects. (1977) (3)
The NHS Health Checks programme: A better alternative (2016) (3)
Antenatal screening for Down’s syndrome, trisomy 18, and trisomy 13: Reporting a single screening result for all three (2015) (3)
Screening for ovarian cancer. Still controversial, but encouraging. (1993) (3)
Safety of cholesterol reduction remains in doubt (1994) (3)
Personalized medicine: hope or hype. (2012) (3)
Comparison of an ELISA with a RIA Method for Serum Alpha-Fetoprotein Determination in Screening for Fetal Neural Tube Defects (1986) (3)
The area under the ROC curve: Is it a valid measure of screening performance? (2014) (3)
Preventing oesteoporosis: Authors' reply (1991) (3)
Inhibin‐A regression (1999) (2)
The serum folate response to the US mandatory fortification of grain products with folic acid. (2002) (2)
Sequential integrated antenatal screening for Down’s syndrome, trisomy 18 and trisomy 13 (2016) (2)
One and two view mammography in breast cancer (1996) (2)
Down's syndrome screening: Value of using free β‐hCG (1995) (2)
The meaning of "screening" (1990) (2)
Controlled anti-natal thyroid screening study (CATS) - early results (2004) (2)
Meta-analysis audit trail (2008) (2)
Passive smoking and lung cancer: increased risk is not disputed (2000) (2)
FETAL LOSS AFTER AMNIOCENTESIS (1978) (2)
Importance of getting the right UK folic acid fortification policy (2022) (2)
Mandatory UK folic acid fortification (2021) (2)
Bigg's Cost Accounts (1984) (2)
Respnose to the letter from Dr Lee (1991) (2)
Ethics of antenatal and neonatal screening (2000) (2)
The principal investigators respond (1997) (2)
All screening is universal (2001) (2)
The polypill concept. (2010) (2)
Serum cholesterol concentrations in parasuicide (1995) (2)
Discounting financial costs and health benefits in public health programmes (2016) (2)
Directory of On-Going Research in Cancer Epidemiology 1989/90 (1990) (2)
Interpretation of negative epidemiological evidence for carcinogenicity. Proceedings of a symposium held in Oxford, 4-6 July 1983. (1985) (2)
Sodium and cardiovascular disease (2016) (2)
Immonuassay Screening for Open Neural-tube Defects: Practical Aspects (1981) (2)
Dietary salt and blood pressure. (1994) (2)
Allowing for ethnic group in antenatal screening for Down's syndrome (2013) (2)
Antenatal reflex DNA screening for trisomy 18 and trisomy 13 in addition to Down’s syndrome (2016) (2)
Under new management! Medical Screening Society buys Journal of Medical Screening (2003) (2)
Seeking other disorders within antenatal serum screening programmes for Down's syndrome (2002) (2)
Starting the polypill: the use of a single age cut-off in males and females (2016) (2)
Familial hypercholesterolaemia: screening needs a fresh approach. (2007) (2)
Reporting of screening results (1999) (2)
First-trimester increased nuchal translucency as a prenatal sign of Zellweger syndrome (2004) (2)
Consensus conference on breast cancer screening. Paris, February 4-5, 1993. Report of the Evaluation Committee. (1994) (2)
Hydrazine: epidemiological evidence. (1985) (2)
The B4-you-conceive pill (1996) (2)
The triple test. (2014) (2)
Down syndrome fetal loss rate in early pregnancy (2000) (2)
Unified prenatal screening for Down's syndrome and pre-eclampsia. (2011) (2)
Obesity and public health law. (2006) (1)
Screening mammography re-evaluated (2000) (1)
Corrigendum for Wald NJ, Bestwick JP, Huttly WJ, Aldis J, Borrell A, Goodburn S & Mills I (2018) https://doi.org/10.1002/pd.5381 (2019) (1)
Two under-recognized limitations of number needed to treat. (2020) (1)
NHS announces a pilot of a blood test for early detection of many cancers (2021) (1)
Alpha-fetoprotein in antenatal diagnosis of neural tube defects. (1978) (1)
MRC/BHF Heart protection study. Authors' reply (2002) (1)
Pilot Screening Trial : baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening ' (2016) (1)
Reply to Professor Hook (2004) (1)
The target plot: a new way of displaying the performance of a screening test (1999) (1)
Screening for cardiovascular disease: Concerns with a Norwegian proposal (2011) (1)
European Society of Mastology Consensus conference on breast cancer screening Paris, 4-5 February, 1993. Report of the evaluation committee. (1994) (1)
Long term effects of advice to reduce dietary salt. Salt needs to be reduced in manufacturing and processing food. (2003) (1)
Serum marker truncation limits in first trimester antenatal screening for trisomy 18 (2018) (1)
Truncation limits for CT marker ratios in prenatal screening for Down syndrome (2007) (1)
Cost and efficacy comparison of prenatal recall and reflex DNA screening for trisomy 21, 18 and 13 (2019) (1)
Paying for publication (2007) (1)
JMS Online at a screen near you: www.jmedscreen.com (2001) (1)
Apolipoproteins and prediction of fatal myocardial infarction. Authors' reply (2002) (1)
When Guidelines Cause Hypertension. (2018) (1)
Death from ischaemic heart disease. (1977) (1)
The causation of neural tube defects – a journey of discovery and the challenge of prevention (2012) (1)
Certification of competence in performing specific procedures or tests in screening practice (2003) (1)
Antenatal screening for Down’s syndrome: Revised nuchal translucency upper truncation limit due to improved precision of measurement (2020) (1)
F Child-Parent Screening for Familial Hypercholesterolemia (2011) (1)
SHOULD ULTRASOUND BE USED TO ESTIMATE GESTATIONAL AGE IN THE SCREENING AND ANTENATAL DIAGNOSIS OF OPEN NEURAL TUBE DEFECTS? (1980) (1)
ULTRASOUND BIPARIETAL DIAMETER IN SPINA BIFIDA (1986) (1)
The Canadian Recommendations on Screening for Type 2 Diabetes (2012) (1)
Section 3: Prenatal screening and diagnosis of open neural tube defects (1981) (1)
Recurrent neural tube defects, risk factors and vitamins (1986) (1)
Lowering cholesterol concentrations and mortality (1990) (1)
The President's message. (1973) (1)
Misleading meta-analysis (1995) (1)
Prenatal maternal plasma DNA screening for cystic fibrosis: A computer modelling study of screening performance (2017) (1)
epidemiological studies context of expectations from prospective meta-analysis of 147 randomised trials in the prevention of cardiovascular disease: Use of blood pressure lowering drugs in the (2009) (1)
Efficacy and effectiveness (2021) (1)
Serum screening for Down's syndrome: Authors' reply (1989) (1)
Antenatal Screening for Hypothyroidism and Childhood Cognitive Impairment (2013) (1)
Contingent screening for Down syndrome (2008) (1)
MORTALITY AND MORBIDITY IN RELATION TO SOCIAL CLASS (1972) (1)
The estimation of gestational age of pregnancy for use in screening for Down syndrome using ultrasound measurements and embryo transfer date (2012) (1)
USE OF FREE BETA -HCG IN DOWN'S SYNDROME SCREENING. AUTHORS' REPLY (1993) (1)
Folic acid and prevention of neural-tube defects (1997) (1)
Maternal serum free alpha- and free beta-human chorionic gonadotrophin in pregnancies with insulin-dependent diabetes mellitus: implications for screening for Down's syndrome. (1994) (1)
Risk or chance (2022) (1)
Evaluation of a proposed mixture model to specify the distributions of nuchal translucency measurements in antenatal screening for Down's syndrome (2010) (1)
SCREENING FOR NEURAL-TUBE DEFECTS (1980) (1)
Authors’ reply (2009) (0)
Silent Prevention (1979) (0)
Authors' reply (1998) (0)
Some clarity in the management of DCIS in breast cancer screening (2011) (0)
Radiological interventions and outcomes (2016) (0)
Directory of On-Going Research in Cancer Epidemiology. 1991 (1991) (0)
Dr Jacob (Jack) Canick – an appreciation (2013) (0)
The illusion of polygenic disease risk prediction (2019) (0)
Polypill in Persons without Cardiovascular Disease. (2021) (0)
Multi-marker risk-based screening for prostate cancer (2022) (0)
European Society of Mastology. Consensus Conference on Breast Cancer Screening. Paris, 4-5 February, 1993. Report of the Evaluation Committee. (1994) (0)
Guidance on terminology (2023) (0)
Formulation destinee a la prevention de maladies cardio-vasculaires (2001) (0)
Biochemical screening. (1990) (0)
Estimating risk of Down's syndrome. (1991) (0)
Authors' reply (1985) (0)
Trial randomisation method (outlined in Chapter 2) (2016) (0)
Nonsmokers exposed to other people's tobacco smoker have an increased risk for lung cancer (1998) (0)
Rudnicka meta-analysis disease , and stroke : systematic review and lipoprotein cholesterol , ischaemic heart Quantifying effect of statins on low density (2003) (0)
Response to Walker (2018) (0)
EXAMINATION FOR INFLUENZA IgA AND IgM ANTIBODIES DEFECTS IN PREGNANCIES ASSOCIATED WITH FETAL NEURAL-TUBE (1981) (0)
An Emmonsia Species Causing Disseminated Infection in South Africa (2014) (0)
Are screening practice ethics committees needed? (2021) (0)
Singleton versus duplicate assays in maternal serum screening - Reply (2001) (0)
A simple method to allow for guanine-cytosine amplification error in prenatal DNA screening for trisomy 18. (2019) (0)
Occupational exposuretohydrazine andsubsequent risk ofcancer (1984) (0)
Suspended judgment--does taking extra vitamins prevent spina bifida? (1990) (0)
Recruitment of participants (2016) (0)
Antenatal reflex DNA screening for Down’s syndrome using total instead of free B-hCG in the Combined test (2016) (0)
Down's syndrome screening: value of using free beta-hCG. (1995) (0)
Testing should be in all women (1995) (0)
James Edward Haddow, MD 1934–2020 (2020) (0)
Response to Hooper et al (2017) (0)
Authors' Reply (1996) (0)
Medical Screening Society members’ talks (2018) (0)
In response to Nicolaides (2004) (0)
Validation of a monoclonal unconjugated estriol antibody for use in prenatal maternal serum screening. (2023) (0)
Reply (2012) (0)
Cochrane report on lowering blood pressure (2014) (0)
Response to Nicolaides (2004) (0)
The Need to Interpret the Results of a Clinical Trial in the Context of Other Evidence. (2017) (0)
Law more than 80 % A strategy to reduce cardiovascular disease (2003) (0)
Nuchal translucency and gestational age. Authors' reply (2004) (0)
Commentary: silent prevention (2004) (0)
Abstract: 572 THE NEED TO SIMPLIFY CLINICAL GUIDELINES (2009) (0)
Genetic Testing (2011) (0)
Abstract: S5-7 TAKING THE POLYPILL CONCEPT FORWARD (2009) (0)
Details of the Liverpool Lung Project risk model (version 2) (2016) (0)
One and two view mammography in breast cancer - Reply (1996) (0)
Authors' reply (1998) (0)
Unconjugated estriol values between 14 and 22 weeks of gestation in relation to prenatal screening for Down syndrome (2012) (0)
Maternal serum alpha-fetoprotein and diabetes mellitus. (1981) (0)
The Risk-Screening Converter (2023) (0)
Antenatal screening policies for Down's syndrome (2002) (0)
[Smoking and its relations to lung cancer and coronary heart disease]. (1978) (0)
United Kingom lung cancer screening (UKLS) trial [Conference abstract] (2011) (0)
SCREENING FOR NEURAL-TUBE DEFECTS (1980) (0)
CORRESPONDENCE (1981) (0)
Authors' reply (1996) (0)
Letter: Smoking tables for carbon monoxide? (1973) (0)
The press, press releases, and raising unwarranted expectations (2013) (0)
Jacob (Jack) Canick (28 November 1944–19 May 2013) (2013) (0)
Antenatal screening for Down's syndrome (1992) (0)
First-trimester nuchal translucency screening. (2002) (0)
Workshop on amniotic fluid Acetylcholinesterase. (1982) (0)
risk of cancer . hydrazine and subsequent Occupational exposure to (2005) (0)
Patient consent to the use of human tissue taken from NHS patients, and stored for research purposes (2017) (0)
Screening for neural-tube defects. (Letter) (1978) (0)
Audit of Down's syndrome screening not valid (2017) (0)
Antenatal Screening for Down Syndrome Using the Integrated Test (2006) (0)
Bmj Lung Cancer and Passive Smoking (2015) (0)
Reply to letter (2001) (0)
Executive summary Antenatal screening for Down’s syndrome (1998) (0)
Authors' reply (1996) (0)
Summary report of UK Lung Cancer Screening sample quality control (2016) (0)
Statement from panel on antenatal screening for Down syndrome (1999) (0)
Correction: The illusion of polygenic disease risk prediction (2021) (0)
VITAMIN A AND CANCER (1980) (0)
Ultrasound fetal femur length measurement in the screening for Down's syndrome (1990) (0)
MATERNAL SERUM-ALPHA-FETOPROTEIN AND LOW BIRTH WEIGHT (1978) (0)
CARBON MONOXIDE AND SMOKING (1974) (0)
‘Risk or chance’: Authors’ response (2022) (0)
Lung Cancer RCT Pilot Screening Trial : baseline fi ndings from the screening arm provide evidence for the potential implementation of lung cancer screening (2016) (0)
Allowing for ethnic group in antenatal screening for Down’s syndrome. (2013) (0)
Adipose tissue trans fatty acids and coronary heart disease. (1995) (0)
Risk factor thresholds. Author's reply (2002) (0)
Estimation of risk in second trimester serum screening for Down syndrome among women who have already had first trimester screening. (2002) (0)
Author's Reply (2005) (0)
Cholesterol, statins, and mortality (2008) (0)
Lives saved by breast cancer screening (2017) (0)
Computed tomography scan findings and the early outcome of patients referred to the multidisciplinary team (2016) (0)
Screening for osteopororis. Author's replyl (1992) (0)
Author's reply (1987) (0)
Medical screening (2020) (0)
Cross trimester marker ratios: parameter estimates valid with no inconsistency (2006) (0)
Medical Screening: The Way Forward (1994) (0)
Assessing Risk Factors as Potential Screening Tests (2017) (0)
NTD SCREENING BY ULTRASOUND (1983) (0)
UK Lung Cancer Screening trial documentation (2016) (0)
Blood pressure meta-analysis highlights an implementation gap (2022) (0)
Response to Gotzsche (2018) (0)
Authors' Reply (1996) (0)
Screening for future cardiovascular disease: the need for simplification (2017) (0)
When alternatives to screening should be the priority (2022) (0)
Postscript to ‘Folic acid and neural tube defects: Discovery, debate and the need for policy change’ (2022) (0)
Antenatal screening for Down's syndrome. (1992) (0)
SNPs and coronary heart disease (2011) (0)
Cholesterol and all-cause mortality in Honolulu (2001) (0)
Authors' Reply (1996) (0)
Which gestational age estimate to use in AFP screening for spina bifida? (2005) (0)
Authors' reply (1996) (0)
Reduction in breast cancer mortality from mammographic screening (2017) (0)
The Reply. (2016) (0)
Recurrent false‐positives in AFP screening for open neural tube defects (2004) (0)
Letter: Carbon monoxide and smoking. (1974) (0)
Effect of smoking status on inhibin‐A in second‐trimester prenatal screening for Down syndrome (2014) (0)
Folate and risk of cardiovascular disease. Authors' reply (2003) (0)
Systematic Reviews of Screening (1997) (0)
based on a meta-analysis hypercholesterolaemia : screening strategy Child-parent screening for familial (2007) (0)
Methodological issues remain unanswered - Authors' response (2017) (0)
Effect on Down syndrome screening performance of adjusting for marker levels in a previous pregnancy (2006) (0)
Alpha‐fetoprotein levels and yolk sac size in the first trimester of pregnancy (1992) (0)
When primary prevention replaces screening (2021) (0)
Use of MoMs (1993) (0)
Nuchal translucency and gestational age - Response to Nicolaides (2004) (0)
Erratum to “Unified prenatal screening for Down's syndrome and pre-eclampsia” [Clinical Biochemistry 44 (2011) 455] (2011) (0)
Medical screening society working groups (2005) (0)
Composition for the prevention of cardiovascular diseases (2001) (0)
Ovulation induction and neural tube defects (1990) (0)
PROFESSOR EDWARD H.KASS, MD, PhD (1990) (0)
PSA as screening test for prostate cancer (1996) (0)
Blood pressure and cardiovascular outcomes: a closer look (2017) (0)
Smoking And Leukaemia: Leukaemia Commoner Among Smokers But Why? (1988) (0)
Nicotine chewing gum in general practice (1984) (0)
Cost of Integrated, sequential and contingent prenatal screening for Down’s syndrome (2018) (0)
Mammography screening for breast cancer (2000) (0)
In response to Nicolaides (2004) (0)
Data tables showing demographics of response and recruitment (2016) (0)
Ischaemic heart disease and cholesterol: Author's reply (1994) (0)
hypothyroidism A randomized double-blind crossover trial to investigate the efficacy of screening for adult (2013) (0)
Authors’ reply (1994) (0)
The Limited Public Health Impact of 'Lifestyle' Change. (2016) (0)

This paper list is powered by the following services:

Other Resources About Nicholas Wald

en.wikipedia.org

What Schools Are Affiliated With Nicholas Wald?

Nicholas Wald is affiliated with the following schools: